SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is trending as the community discusses its potential as a high-speed, EVM-compatible blockchain, with some comparing it to early Ethereum and Solana. The community is focused on its Coinbase listing and potential for staking rewards, while also debating its market cap and long-term viability. Discussions also include speculation around future exchange listings and potential partnerships.

Codatta

XNY (Codatta) is trending amid discussions about its role in powering AI's data future and recent exchange listings. The community highlights its potential for data contributors to earn royalties and its strong performance relative to Bitcoin in the current market. Some traders are pointing to bullish chart patterns and anticipating a breakout.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is trending as community members highlight its strong financials and pipeline, especially Auvelity's potential in treating Alzheimer's agitation. Recent analyst upgrades and positive trial data are fueling optimism, though some caution against over-reliance on pipeline developments. Discussions also include potential buyout scenarios and the impact of regulatory decisions on the stock's future.

Based Chad

Based Chad is trending as community members highlight its relative strength compared to other memecoins amid market dips, emphasizing its diamond-handed community and unique buyback mechanisms. Discussions also suggest a potential connection to Coinbase, with executives reportedly holding the token and the meme gaining traction on the platform. The community anticipates further growth, pointing to upcoming video game integrations and staking opportunities.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as community members discuss potential catalysts, including speculation around upcoming economic data and central bank policy. Bullish sentiment suggests gold's safe-haven appeal is being recognized amid market uncertainty. Discussions also focus on technical analysis, with some eyeing breakout levels and others highlighting overbought conditions.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

BRR is trending as chatter swirls around its upcoming merger vote and potential exposure to Bitcoin, with some highlighting the involvement of Eric Jackson and Anthony Pompliano. The community is speculating on a potential short squeeze and the impact of amendments to the deal, with excitement building for a possible rally.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health ($ELV) is trending as traders discuss options activity and potential upside, while analysts update ratings. Community members are weighing in on the company's valuation and its position relative to competitors within the managed care sector amid political and economic uncertainty impacting the broader healthcare landscape.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

SMMT is trending as traders discuss the potential for a short squeeze, pointing to high short interest and recent insider buying as key factors. Bullish sentiment is fueled by confidence in the company's pipeline and upcoming data releases, while bears express concerns about the impact of trial results on FDA approval and market competition. Community members are actively debating the company's valuation and potential catalysts.

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva SE - ADR

Valneva is trending due to positive Phase 2 booster results for its Lyme disease vaccine, developed in partnership with Pfizer, fueling speculation about a potential buyout. The community is focused on the significant revenue potential of the Lyme vaccine and anticipating Phase 3 trial data. Some investors express caution, referencing past setbacks, while others see the current low trading volume as an opportunity for exponential gains upon positive news.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

UEC is trending as the uranium sector gains momentum, potentially fueled by discussions around bolstering domestic uranium reserves and increasing demand for nuclear energy. Community members are actively watching for a breakout and discussing potential price targets, while also debating the stock's valuation in comparison to peers. Recent options activity suggests heightened interest, further contributing to the stock's current buzz.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Research Analysts Set Expectations for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a report...

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 1,127 shares of the company's stock in a transaction that occurred on Tuesday, November 18th. The stock was...

Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Lexeo Therapeutics in a research report on Thursday. They set an "overweight" rating and a $19.00 price target for the company...

Equities Analysts Set Expectations for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Lexeo Therapeutics in a note issued to investors on...

Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's  What You Should Know

The consensus price target hints at a 124.3% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Lexeo Therapeutics in a report...

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) released its earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by...

Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from Chardan Capital

Chardan Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday...

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?

The consensus price target hints at a 108.2% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LXEO News

LXEOLexeo Therapeutics Inc.